Study on the relationship between serum soluble OX40 ligand and the survival of advanced gastric cancer patients

doi:10.3877/cma.j.issn.1674-0793.2020.04.012

Abstract

Abstract:

Objective

To investigate the relationship between serum soluble OX40 ligand (sOX40L) and survival time in patients with advanced gastric cancer and to provide basis for immunotherapy of gastric cancer.

Methods

From January 2015 to May 2017, 115 patients with advanced gastric cancer admitted to Wuhan Red Cross Hospital and Union Hospital of Tongji Medical College were selected as the observation group, and 91 healthy persons in the same period were in the control group. The level of serum sOX40L in two groups was detected by ELISA, Kaplan-Meier curve was used to analyze the relationship between the level of sOX40L and survival time of patients, COX regression analysis was used for risk factors of advanced gastric cancer.

Results

The level of sOX40L in the observation group was higher than that in the control group (P<0.05). There were 58 cases in high level group (sOX40L ≥20.58 ng/L), 57 cases in low level group (sOX40L < 20.58 ng/L), the level of sOX40L was related to TNM stage, lymph node metastasis and liver metastasis (P<0.05). The median total survival time of high level group was 6.65 months (95% CI: 5.89-7.42), which was shorter than 9.47 months of low level group (95% CI: 8.59-10.36), the difference was statistically significant (P<0.001). Age ≥60 years old, high expression of sOX40L, TNMⅣ stage, lymph node metastasis and liver metastasis were independent risk factors for poor prognosis of advanced gastric cancer.

Conclusions

sOX40L is highly expressed in the serum of patients with advanced gastric cancer, its level is related to TNM stage, lymph node metastasis and liver metastasis. It is an independent risk factor for poor prognosis of patients with gastric cancer.

Key words: Stomach neoplasms, OX40 ligand, Risk factors, Survival analysis

Fang Liu, Lanbin Jiang, Liang Wang, Yanfeng Niu, Yong Xiao, Wanli Zhang. Study on the relationship between serum soluble OX40 ligand and the survival of advanced gastric cancer patients[J]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(04): 290-293.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2020.04.012

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2020/V14/I04/290

Figures/Tables 3

References 17

[1]	Verma R, Sharma PC. Next generation sequencing-based emerging trends in molecular biology of gastric cancer[J]. Am J Cancer Res, 2018, 8(2): 207-225.
[2]	Wöll E, Thaler J, Keil F, et al. Oxaliplatin/Irinotecan/Bevacizumab followed by docetaxel/bevacizumab in inoperable locally advanced or metastatic gastric cancer patients-AGMT_GASTRIC-3[J]. Anticancer Res, 2017, 37(10): 5553-5558.
[3]	Kinami S, Nakamura N, Tomita Y, et al. Precision surgical approach with lymph-node dissection in early gastric cancer[J]. World J Gastroenterol, 2019, 25(14): 1640-1652.
[4]	Ueno H, Blanco P. OX40/OX40L axis: not a friend in autoim-munity[J]. Oncotarget, 2015, 6(26): 21779-21780.
[5]	Liu D, Lu M, Li J, et al. The patterns and timing of recurrence after curative resection for gastric cancer in China[J]. World J Surg Oncol, 2016, 14(1): 305.
[6]	Cho DS, Sun SI, Choo SH, et al. Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma[J]. Scand J Urol, 2016, 50(3): 186-191.
[7]	陈孝杰，朱志军，孙丽莹. OX40/OX40L在诱导移植免疫耐受中的研究进展[J]. 中华微生物学和免疫学杂志, 2018, 38(7): 556-558.
[8]	Liu W, Almo SC, Zang X. Co-stimulate or co-inhibit regulatory T cells, which side to go?[J]. Immunol invest, 2016, 45(8): 813-831.
[9]	Publicover J, Gaggar A, Jespersen JM, et al. An OX40/OX40L interaction directs successful immunity to hepatitis B virus[J]. Sci Transl Med, 2018, 21(10): 433-458.
[10]	Huang L, Wang M, Yan Y, et al. OX40L induces helper T cell differentiation during cell immunity of asthma through PI3K/AKT and P38 MAPK signaling pathway[J]. J Transl Med, 2018, 16(1): 74-83.
[11]	张驰，王丽岳，任浩进, 等. 不同剂量阿托伐他汀对急性冠脉综合征患者HO-1/HbCO系统、血清sOX40L水平影响及其与炎性因子的相关性分析[J]. 疑难病杂志, 2019, 18(5): 437-441.
[12]	Ma J, Li J, Hao Y, et al. Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy[J]. Oncotarget, 2017, 8(40): 67094-67103.
[13]	张晓农，胡续光，李洪秀, 等. 围手术期免疫增强型肠内营养剂对全胃切除患者的影响[J/CD]. 中华普外科手术学杂志（电子版）, 2019, 13(2): 141-143.
[14]	Wang YK, Shen L, Jiao X, et al. Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP[J]. World J Gastroenterol, 2018, 24(2): 266-273.
[15]	陈诚，王玲，唐家喜. 中晚期胃癌患者细胞免疫治疗后的免疫状态观察及影响因素分析[J]. 免疫学杂志, 2018, 34(12): 1077-1081, 1104.
[16]	Sun L, Chen C, Wu J, et al. TSLP-activated dendritic cells induce T helper type 2 inflammation in Aspergillus fumigatus keratitis[J]. Exp Eye Res, 2018, 171(1): 120-130.
[17]	张李琛，张进萍，邹云莲. 胃癌免疫治疗的研究进展[J]. 癌症进展, 2019, 17(16): 1875-1878.

组别	例数	性别(例)		年龄(岁)^a	体质指数(kg/m²)^a	TNM分期[例(%)]		淋巴结转移[例(%)]		肝转移[例(%)]
组别	例数	男	女	年龄(岁)^a	体质指数(kg/m²)^a	Ⅲ	Ⅳ	有	无	有	无
高水平组	58	31	27	53.58±6.74	24.02±4.25	15(25.86)	43(74.14)	41(70.69)	17(29.31)	36(62.07)	22(37.93)
低水平组	57	33	24	52.31±5.87	23.47±3.54	29(50.88)	28(49.12)	27(47.37)	30(52.63)	18(31.58)	39(68.42)
统计值	?	0.230		1.077	0.753	7.615		6.470		10.730
P值	?	0.631		0.284	0.453	0.006		0.011		0.001

组别	例数	性别(例)		年龄(岁)^a	体质指数(kg/m²)^a	TNM分期[例(%)]		淋巴结转移[例(%)]		肝转移[例(%)]
组别	例数	男	女	年龄(岁)^a	体质指数(kg/m²)^a	Ⅲ	Ⅳ	有	无	有	无
高水平组	58	31	27	53.58±6.74	24.02±4.25	15(25.86)	43(74.14)	41(70.69)	17(29.31)	36(62.07)	22(37.93)
低水平组	57	33	24	52.31±5.87	23.47±3.54	29(50.88)	28(49.12)	27(47.37)	30(52.63)	18(31.58)	39(68.42)
统计值	?	0.230		1.077	0.753	7.615		6.470		10.730
P值	?	0.631		0.284	0.453	0.006		0.011		0.001

变量	单因素分析			多因素分析
变量	HR	95%置信区间	P值	HR	95%置信区间	P值
性别（男vs女）	2.136	1.136~4.015	0.095	—	—	—
年龄（<60岁 vs ≥60岁）	1.649	1.152~2.360	0.021	1.248	0.944~1.651	0.033
体质指数（<24 kg/m² vs ≥24 kg/m²）	2.604	2.155~3.146	0.315	—	—	—
sOX40L表达（高水平vs低水平）	1.828	1.256~2.660	<0.001	1.655	1.204~2.275	<0.001
TNM分期（Ⅲ期 vs Ⅳ期）	3.231	1.809~5.769	<0.001	2.125	1.162~3.888	0.014
淋巴结转移（有vs无）	5.893	2.703~12.848	<0.001	2.742	1.186~6.340	0.018
肝转移（有vs无）	3.872	2.341~6.405	<0.001	3.093	1.762~5.431	<0.001

变量	单因素分析			多因素分析
变量	HR	95%置信区间	P值	HR	95%置信区间	P值
性别（男vs女）	2.136	1.136~4.015	0.095	—	—	—
年龄（<60岁 vs ≥60岁）	1.649	1.152~2.360	0.021	1.248	0.944~1.651	0.033
体质指数（<24 kg/m² vs ≥24 kg/m²）	2.604	2.155~3.146	0.315	—	—	—
sOX40L表达（高水平vs低水平）	1.828	1.256~2.660	<0.001	1.655	1.204~2.275	<0.001
TNM分期（Ⅲ期 vs Ⅳ期）	3.231	1.809~5.769	<0.001	2.125	1.162~3.888	0.014
淋巴结转移（有vs无）	5.893	2.703~12.848	<0.001	2.742	1.186~6.340	0.018
肝转移（有vs无）	3.872	2.341~6.405	<0.001	3.093	1.762~5.431	<0.001

Please choose a citation manager

Content to export